Revolutionary Weight Loss Pill by Eli Lilly Promises 12% Weight Loss Success
Eli Lilly has recently announced the groundbreaking results of its oral weight loss medication, orforglipron. Clinical trials have shown that patients lost an average of 12.4% of their body weight (27.3 pounds) over a period of 72 weeks. This once-daily pill, which does not require any food or water restrictions, is a major breakthrough in obesity treatment as it is the first needle-free GLP-1 alternative.
The pharmaceutical giant is now preparing for global regulatory submissions by the end of 2025, with potential FDA approval as early as 2026. Unlike existing injectable treatments like Wegovy and Zepbound that cost around $1,000 monthly, the pill format of orforglipron could be easier and cheaper to manufacture. This could potentially improve access for millions of patients.
Apart from weight loss, the medication has also shown significant improvements in heart health markers. This includes:
- Reduced cholesterol
- Lowered blood pressure
- Decreased inflammatory markers
Currently, only 8 million Americans use obesity medications despite an estimated 170 million who could benefit. CEO David Ricks stated that the company is ‘making substantial investments to meet anticipated demand at launch‘.